Payment overview · 2025
General Payments
$1,001.44
50 reported records · 11 companies
Healthcare provider profile · identity verified
Michael David Settecase, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · OLYMPIA FIELDS, IL · NPI 1447368055
Verified facts
What the public records show
CMS Open Payments records show Michael David Settecase, D.O. received $1,001.44 in general payments during 2025 across 50 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Paxlovid, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 414 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 414 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $227.29 | 22.7% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.70 | 17.1% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $156.43 | 15.6% | 10 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $117.82 | 11.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $112.89 | 11.3% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $69.39 | 6.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.72 | 4.1% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $29.78 | 3.0% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $28.28 | 2.8% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $28.23 | 2.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.91 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,001.44 | 50 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $125.45 | 9 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $125.11 | 9 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.93 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $103.96 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $90.48 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $73.63 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $69.39 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $60.19 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $57.63 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $49.82 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.72 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $29.78 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $28.28 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $28.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.17 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $19.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $14.09 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $10.14 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $10.14 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 414 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
414 | 59 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
414 | 59 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1269 | 313 |
| Amlodipine Besylate | Amlodipine Besylate | 1004 | 247 |
| Lisinopril | Lisinopril | 703 | 161 |
| Levothyroxine Sodium | Levothyroxine Sodium | 586 | 116 |
| Metformin Hcl | Metformin Hcl | 490 | 131 |
| Pantoprazole Sodium | Pantoprazole Sodium | 475 | 100 |
| Gabapentin | Gabapentin | 464 | 98 |
| Metoprolol Succinate | Metoprolol Succinate | 462 | 111 |
| Tamsulosin Hcl | Tamsulosin Hcl | 454 | 114 |
| Furosemide | Furosemide | 422 | 84 |
| Eliquis | Apixaban | 414 | 59 |
| Omeprazole | Omeprazole | 398 | 103 |
| Clopidogrel | Clopidogrel Bisulfate | 390 | 65 |
| Losartan Potassium | Losartan Potassium | 364 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 347 | 80 |
| Simvastatin | Simvastatin | 315 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 291 | 54 |
| Hydrochlorothiazide | Hydrochlorothiazide | 286 | 85 |
| Alprazolam | Alprazolam | 264 | 66 |
| Potassium Chloride | Potassium Chloride | 259 | 55 |
| Carvedilol | Carvedilol | 256 | 66 |
| Allopurinol | Allopurinol | 253 | 46 |
| Sertraline Hcl | Sertraline Hcl | 238 | 33 |
| Fluticasone Propionate | Fluticasone Propionate | 209 | 67 |
| Montelukast Sodium | Montelukast Sodium | 208 | 51 |
| Tramadol Hcl | Tramadol Hcl | 204 | 50 |
| Donepezil Hcl | Donepezil Hcl | 195 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 38 |
| Famotidine | Famotidine | 190 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 180 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 177 | 67 |
| Hydralazine Hcl | Hydralazine Hcl | 177 | 38 |
| Levetiracetam | Levetiracetam | 174 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 152 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 42 |
| Januvia | Sitagliptin Phosphate | 122 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 118 | 31 |
| Meclizine Hcl | Meclizine Hcl | 116 | 31 |
| Warfarin Sodium | Warfarin Sodium | 115 | 13 |
| Memantine Hcl | Memantine Hcl | 112 | 17 |
| Trazodone Hcl | Trazodone Hcl | 112 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 17 |
| Jardiance | Empagliflozin | 110 | 22 |
| Spironolactone | Spironolactone | 108 | 38 |
| Benazepril Hcl | Benazepril Hcl | 101 | 19 |
| Xarelto | Rivaroxaban | 99 | 13 |
| Metformin Hcl Er | Metformin Hcl | 91 | 27 |
| Prednisone | Prednisone | 90 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 87 | 28 |
| Ezetimibe | Ezetimibe | 83 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 81 | 20 |
| Lorazepam | Lorazepam | 81 | 15 |
| Bupropion Xl | Bupropion Hcl | 80 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 79 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 78 | 23 |
| Mirtazapine | Mirtazapine | 77 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 77 | 22 |
| Clonazepam | Clonazepam | 75 | 17 |
| Nifedipine Er | Nifedipine | 75 | 19 |
| Sucralfate | Sucralfate | 75 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 73 | 17 |
| Finasteride | Finasteride | 69 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 68 | suppressed |
| Glimepiride | Glimepiride | 60 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 57 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 56 | 13 |
| Lovastatin | Lovastatin | 56 | 15 |
| Ibuprofen | Ibuprofen | 55 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 55 | 20 |
| Ursodiol | Ursodiol | 55 | suppressed |
| Baclofen | Baclofen | 52 | 12 |
| Entresto | Sacubitril/Valsartan | 52 | 12 |
| Glipizide | Glipizide | 52 | 14 |
| Primidone | Primidone | 52 | suppressed |
| Atenolol | Atenolol | 50 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 15 |
| Enalapril Maleate | Enalapril Maleate | 50 | suppressed |
| Latanoprost | Latanoprost | 50 | 17 |
| Meloxicam | Meloxicam | 50 | 17 |
| Metoclopramide Hcl | Metoclopramide Hcl | 50 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 49 | suppressed |
| Irbesartan | Irbesartan | 48 | 20 |
| Amiodarone Hcl | Amiodarone Hcl | 47 | 14 |
| Risperidone | Risperidone | 44 | suppressed |
| Synthroid | Levothyroxine Sodium | 44 | 12 |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | 12 |
| Pregabalin | Pregabalin | 41 | 13 |
| Diazepam | Diazepam | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 39 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 39 | suppressed |
| Glipizide Er | Glipizide | 39 | 12 |
| Azithromycin | Azithromycin | 38 | 33 |
| Clonidine Hcl | Clonidine Hcl | 38 | 11 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Klor-Con M20 | Potassium Chloride | 37 | 13 |
| Naproxen | Naproxen | 37 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 35 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Lamotrigine | Lamotrigine | 35 | suppressed |
| Nystatin | Nystatin | 34 | 12 |
| Ozempic | Semaglutide | 34 | suppressed |
| Fenofibrate | Fenofibrate | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 21 |
| Valsartan | Valsartan | 32 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 32 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 32 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 31 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Myrbetriq | Mirabegron | 30 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 25 |
| Sevelamer Carbonate | Sevelamer Carbonate | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Torsemide | Torsemide | 28 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 27 | suppressed |
| Olanzapine | Olanzapine | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 25 | suppressed |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 12 |
| Ramipril | Ramipril | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Fentanyl | Fentanyl | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Topiramate | Topiramate | 22 | suppressed |
| Trulicity | Dulaglutide | 22 | suppressed |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 20 |
| Ketoconazole | Ketoconazole | 21 | 13 |
| Tradjenta | Linagliptin | 21 | suppressed |
| Xifaxan | Rifaximin | 21 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 19 | 11 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Ranolazine Er | Ranolazine | 19 | suppressed |
| Steglatro | Ertugliflozin Pidolate | 19 | suppressed |
| Budesonide | Budesonide | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Lidocaine | Lidocaine | 17 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 16 | suppressed |
| Alprazolam Xr | Alprazolam | 16 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Insulin Lispro | Insulin Lispro | 16 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Niacin Er | Niacin | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 14 | suppressed |
| Daptomycin | Daptomycin | 14 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Methadone Hcl | Methadone Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | suppressed |
| Calcium Acetate | Calcium Acetate | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 13 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 13 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Chlordiazepoxide Hcl | Chlordiazepoxide Hcl | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Ertapenem | Ertapenem Sodium | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Xanax | Alprazolam | 12 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 11 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 11 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Glyburide | Glyburide | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Rufinamide | Rufinamide | 11 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 11 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,001.44 · 50 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, CAMZYOS, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FARXIGA, KISUNLA, Korlym, MOUNJARO, NURTEC ODT, Ozempic, PAXLOVID, PREVNAR 20, QULIPTA, REPATHA, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Veozah, Wegovy, ZEPBOUND, ZORYVE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error